FDA Grants Approval to UCB’s Bimzelx (bimekizumab-bkzx) for Moderate to Severe Plaque Psoriasis Treatment

FDA Grants Approval to UCB’s Bimzelx (bimekizumab-bkzx) for Moderate to Severe Plaque Psoriasis Treatment

UCB, a global biopharmaceutical company, has announced the approval of Bimzelx® (bimekizumab-bkzx) by the U.S. Food and Drug Administration (FDA)…

Read More »